In the United States, innovative, high-quality diagnostic testing options and automation solutions for the clinical laboratory and point-of-care markets are made available under the Wampole^TM brand name.

Wampole^TM ELISA II

A leader in ELISA technology, the Wampole^TM brand provides clinical laboratories with one of the broadest line of ELISA tests in the industry.  Over 60 assays are available across a broad menu, including autoimmune disease, bladder cancer, cardiac risk assessment, enteric disease, infectious disease, STDs, and osteoporosis.  Most assays use interchangeable substrate, stop solution, and wash buffer.  This uniformity of reagents allows for ease of automation with microtiter processing systems.

With standard assay protocols for faster integration into the busy laboratory, Wampole^TM Infectious Disease ELISA products provide increased reliability and run-to-run consistency.

The Wampole^TM NMP22 ELISA test is the first and only test for the screening and monitoring of bladder cancer patients.

State-of-the-art monoclonal and monoclonal/polyclonal antibody-based technology is available in the enteric disease line of products. 

Other advanced technology found only in WAMPOLE^TM ELISA II test kits is SAVE Diluent™, a sample addition verification system that assures no well has been missed.  By changing color from yellow to purple, it is a visual place keeper when preparing manual assays and a rapid verifier of proper instrument performance when running automated platforms. 

Wampole^TM ELISA II test kits are capable of being run in a manual, semi-automated or fully automated capacity with customized instrumentation packages available to suit individual laboratory needs.

Wampole^TM ELISA II kits provide flexible testing, with simple procedures, a broad menu and confidence in the results.

To find out more go to www.invernessmedicalpd.com